Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Canary Islands, first European destination in ROBLOX17.1.2025 13:00:00 CET | Press release
Turismo de Canarias presents Find the Seasouls, an interactive experience within ROBLOX designed to promote environmental care in new generations, calling for respect for natural parks, protected spaces and the biodiversity of the islands
Nomination period for the Broermann Medical Innovation Award started17.1.2025 12:17:33 CET | Press release
Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields
Effective immediately: French purchasing group Francap starts pooling procurement of their strong private label brands under the international umbrella of the EMD Alliance17.1.2025 12:00:00 CET | Press release
Right at the start of 2025, the European Marketing Distribution (EMD) network is once again demonstrating the additional benefits that cooperation between renowned distributors can generate for customers in the retail sector: The latest example is a new cooperation on the joint procurement of private labels in France with the renowned buying group Francap, who serves 10 local retailers, representing over 2,200 points of sale, including the French operations of EMD's Belgian partner Colruyt. As a result, French consumers can now enjoy even more attractive private label product ranges in the affiliated Francap shops - and suppliers in France gain new and valuable access to the global sales markets of the EMD retail alliance.
LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships14.1.2025 13:36:14 CET | Press release
14.01.2025 Andernach – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies.
FEV Group: FEV develops AI-supported driver monitoring system CogniSafe9.1.2025 11:05:03 CET | Press release
Aachen – FEV, a leading global innovation driver for the mobility of tomorrow, presents CogniSafe, a state-of-the-art Driver Monitoring System (DMS) that significantly increases road safety. The system uses advanced technologies such as deep learning and computer vision to monitor driver conditions such as distraction, fatigue and inattention in real time and under even the most challenging conditions.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom